drugset / Trial / NCT02231671
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to see how ALS-008176 is taken up, broken down, and removed from the body.
Timeline
- Start
- 2014-08-31
- Primary completion
- 2014-09-30
- Completion
- 2014-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALS-008112 | Unknown | 100 ug | Intravenous |
| Subject | Lumicitabine | Small molecule | 375 mg | Oral |